RF32 | PSUN46 Impact of Hyperparathyroidism on Atrial Fibrillation In-Hospital Outcomes: A Nationwide Perspective

Abstract

Abstract Background Hyperparathyroidism, associated with calcium abnormalities has an increased probability of developing arrhythmias. However, there are very few studies to demonstrate the significance of hyperparathyroidism on Atrial Fibrillation (A-fib). Methods This is a retrospective cohort study using the 2017-2018 National Inpatient Sample. Patients with a primary discharge diagnosis of A-fib were extracted with ICD10. Patients with hyperparathyroidism were extracted as a secondary diagnosis. Demographics, clinical complications were compared, and outcomes were assessed using linear and logistic regression models to adjust for confounders. Results A total of 649,179 patients (Age >18) were identified with A-fib as the primary diagnosis, and amongst them, 6254 had hyperparathyroidism. Notably, the patients with Hyperparathyroidism and A-fib were more likely to be female and blacks (26.8 vs 8). In-hospital mortality was higher in A-fib patients with hyperparathyroidism (2%) compared to A-fib patients without hyperparathyroidism (0.84%), with a crude odds ratio of 2.4 and adjusted odds ratio of 2.65 (p<0.001). Mean length of stay (LOS) was greater in hyperparathyroidism patients (4.5 vs 3.2 days), with an adjusted odds ratio of 1.26, (p<0.001). Similarly, mean total charges were also significantly higher in hyperparathyroidism patients ($53792 vs $39128). Conclusions Among patients with atrial fibrillation, those who have hyperparathyroidism as comorbidity are associated with more in-hospital mortality, LOS, and total charges. Further studies are required to study the causation of this association. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m., Monday, June 13, 2022 12:54 p.m. - 12:59 p.m.